ST Germain D J Co. Inc. Grows Position in Pfizer Inc. $PFE

ST Germain D J Co. Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,373 shares of the biopharmaceutical company’s stock after purchasing an additional 4,694 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Pfizer were worth $688,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. FCG Investment Co purchased a new stake in shares of Pfizer during the second quarter valued at approximately $356,000. New Insight Wealth Advisors lifted its holdings in Pfizer by 23.3% in the 2nd quarter. New Insight Wealth Advisors now owns 167,834 shares of the biopharmaceutical company’s stock worth $4,068,000 after buying an additional 31,696 shares during the period. BankPlus Wealth Management LLC lifted its holdings in Pfizer by 8.3% in the 2nd quarter. BankPlus Wealth Management LLC now owns 17,830 shares of the biopharmaceutical company’s stock worth $432,000 after buying an additional 1,371 shares during the period. LS Investment Advisors LLC lifted its holdings in Pfizer by 12.1% in the 2nd quarter. LS Investment Advisors LLC now owns 90,179 shares of the biopharmaceutical company’s stock worth $2,186,000 after buying an additional 9,727 shares during the period. Finally, A. D. Beadell Investment Counsel Inc. lifted its holdings in Pfizer by 2.0% in the 2nd quarter. A. D. Beadell Investment Counsel Inc. now owns 51,161 shares of the biopharmaceutical company’s stock worth $1,240,000 after buying an additional 1,000 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, September 20th. Bank of America increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Trading Up 0.6%

PFE opened at $23.75 on Friday. The stock has a market cap of $135.03 billion, a PE ratio of 12.63, a PEG ratio of 0.76 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50 day moving average of $24.55 and a 200-day moving average of $24.14. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.